Thrombocytopenia Treatment Market Analysis and Trends 2020 – Global Industry Growth by Size, Share, Demand, Replacement Surgeries, Advanced Technology, Emerging Market and Forecast to 2026
Global Thrombocytopenia Treatment Market – Insights
Thrombocytopenia is characterized by a low blood platelet count majorly due to inefficient production of platelets, platelet splenic sequestration, and accelerative destruction of platelets. The condition can be inherited or acquired. Bone marrow failure syndrome such as myelodysplastic syndrome and aplastic anemia may lead to ineffective production of thrombocytes. According to the study Frequency of Thrombocytopenia, published in the Professional Medical Journal in 2014, the frequency of thrombocytopenia is higher for people aged 60 years and above and suffering from non-cirrhotic liver disease.
*The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1484
Global Thrombocytopenia Treatment Market Taxonomy:
By Drug Class:
- Lysosomal Enzyme
- Platelet Stimulating Agent
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Exclusive offer!!! Purchase the report at a discounted rate!!!
Apply Promo Code “CMIFIRST1000” and Get Up to 30% Discount
Quick Buy – Thrombocytopenia Treatment Market Research Report: https://bit.ly/3vSly5P
Global Thrombocytopenia Treatment Market: Drivers
Increasing prevalence of thrombocytopenia is expected to boost growth of the global thrombocytopenia treatment market over the forecast period. The risk of developing thrombocytopenia is much higher for chronic Hepatitis C cases. In 2014, according to World Health Organization (WHO), the prevalence of Hepatitis C was lower in Americas and Europe as compared to Africa and Pakistan, where the prevalence of chronic liver disorder was 4-6 % higher than that in Americas and Europe.
Approval and launch of effective and safe therapies for the treatment of thrombocytopenia is expected to boost growth of the global thrombocytopenia treatment market over the forecast period. For instance, in September 2015, Shionogi Inc. received approval for its Lusutrombopag, an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist, from the Pharmaceuticals and Medical Devices Agency of Japan. Lusustrombopag acts specifically on human thrombopoietin (TPO) receptors and stimulates signaling pathways that trigger the proliferation and differentiation of bone marrow cells into megakaryocytes, thereby increasing the blood platelet count. However, patients treated with Lusustrombopag further showed higher counts of blood leukocytes and erythrocyte.
Furthermore, in June 2017, Rigel Pharmaceuticals, Inc. received acceptance for new drug application for its Tavalisse (fostamatinib disodium), a drug is designed to inhibit the spleen tyrosine kinase and treat patients suffering from chronic or persistent immune thrombocytopenia, from the FDA.
Another drug Eltrombopag by Novartis, an oral, non-peptide thrombopoietin receptor agonist has shown efficacy and safety for patients suffering from chronic immune thrombocytopenia (CIT). The drug is approved in the U.S and Europe. The low dose of Eltrombopag is effective and safe for the prevention of CIT. According to Case Reports Hematology, 2017, long-term usage of thrombopoetin (TPO) receptor agonists is safe for patients suffering from chronic lymphocytic leukemia associated with Immune thrombocytopenia, as they are a non-immunosuppressive drugs.
Furthermore, increasing government initiative for fast-track approval of new therapies for the treatment of thrombocytopenia is expected to propel growth of the thrombocytopenia treatment market during the forecast period.
However, from 2023, the global thrombocytopenia treatment market is projected to witness a slowdown in growth due to patent expiration and increasing availability of generics of Promacta and MabThera.
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/1484
Global Thrombocytopenia Treatment Market: Competitive Landscape
Major players in operating in the global thrombocytopenia treatment market include 3SBio Inc., Amarillo Biosciences, Inc., Amgen Inc., Baxalta Incorporated, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cellerant Therapeutics, Inc., Eisai Co., Ltd., Hansa Medical AB, Intas Pharmaceuticals Ltd., Merck & Co., Inc., Momenta Pharmaceuticals, Inc., Myelo Therapeutics GmbH, Neumedicines Inc., Novartis AG, Pfizer Inc., Prophylix Pharma AS, Rigel Pharmaceuticals, Inc., Shionogi & Co., Ltd., STATegics, Inc., and ViroMed Co., Ltd.
Table of Content
Global Thrombocytopenia Treatment Market Research Report
Section 1: Global Thrombocytopenia Treatment Industry Overview
Section 2: Global Economic Impact on Thrombocytopenia Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Thrombocytopenia Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Thrombocytopenia Treatment Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire